ALT screens as a distressed, pre-earnings biotechnology bet masquerading as a value play. With no P/E, no Forward P/E, and a PEG that doesn’t exist, the market has zero earnings visibility, and the -2.1 EPS confirms ongoing losses. An Altman Z-Score of 1.4 signals elevated financial distress risk, while a -48.70% ROIC and -39.20% operating margin show capital destruction, not compounding. At a $421M market cap and a Price/Sales ratio of 500+, this is pure expectation pricing, not fundamental valuation—investors are paying extreme multiples for a company with negative profitability and deteriorating economics.